Jean-Paul Kress, Vor Bio CEO
Vor Bio bounces back with autoimmune drug pact, $175M private placement
In an unexpected turn of events, Vor Bio is back on the fundraising trail and shifting focus to autoimmune disease, less than two months after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
